Marijo Bilusic, MD, PhD, discusses prior research and next steps with the diabetes drug metformin in patients with prostate cancer. Bilusic is a medical oncologist and GU Site Disease Group Lead, Sylvester Comprehensive Cancer Center, Miami Florida. Prior to starting at Sylvester in 2021, he was an associate research physician at the NCI Medical Oncology Service/Genitourinary Malignancy Branch. Also at the NCI, he served as program director of the NIH Hematology Oncology Fellowship Program.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.